# Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection

> **NCT01986543** · PHASE2 · UNKNOWN · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 105 (estimated)

## Conditions studied

- Tuberculosis
- HIV

## Interventions

- **DRUG:** drug administration

## Key facts

- **NCT ID:** NCT01986543
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986543, "Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01986543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*